Drug Profile


Alternative Names: ADX 48621; Dipraglurant-ER; Dipraglurant-IR

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Therapeutics
  • Class Alkynes; Heterocyclic bicyclo compounds; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Anxiety disorders; Drug-induced dyskinesia; Dystonia; Major depressive disorder

Highest Development Phases

  • Phase II Drug-induced dyskinesia; Torticollis
  • Phase I Dystonia
  • Preclinical Major depressive disorder
  • Discontinued Anxiety disorders

Most Recent Events

  • 03 Aug 2017 Phase-II clinical trials in Torticollis in Switzerland (PO) (Addex Therapeutics pipeline, August 2017)
  • 02 Jun 2016 Interim adverse events data from a phase IIa trial in Drug-induced dyskinesia released by Addex Therapeutics
  • 11 Apr 2016 Pharmacodynamics and pharmacokinetics data from a phase I trial in healthy volunteers released by Addex Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top